白细胞介素-23抑制剂治疗炎症性肠病：关键试验和实际考虑。

Q1 Medicine

Current Gastroenterology Reports Pub Date : 2025-06-04 DOI:10.1007/s11894-025-00987-3

Sarah Rotondo-Trivette, William Jennings, David Fudman

{"title":"白细胞介素-23抑制剂治疗炎症性肠病：关键试验和实际考虑。","authors":"Sarah Rotondo-Trivette, William Jennings, David Fudman","doi":"10.1007/s11894-025-00987-3","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review summarizes the literature on IL-23 inhibitors for inflammatory bowel disease and the role of these agents in clinical practice.Recent findings: The last decade has seen several pivotal trials investigating IL-23 inhibitors. These agents are effective in inducing and maintaining remission of moderate-to-severe inflammatory bowel disease, including among those with prior biologic failure, and have low adverse events. IL-23 inhibitors are safe and effective for treatment of moderate-to-severe inflammatory bowel disease and appear more effective than ustekinumab for Crohn's disease. The currently available IL-23 inhibitors likely have similar efficacy, but practical considerations may influence preferences.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":"27 1","pages":"35"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Interleukin-23 Inhibitors for Inflammatory Bowel Disease: Pivotal Trials and Practical Considerations.\",\"authors\":\"Sarah Rotondo-Trivette, William Jennings, David Fudman\",\"doi\":\"10.1007/s11894-025-00987-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose of review: This review summarizes the literature on IL-23 inhibitors for inflammatory bowel disease and the role of these agents in clinical practice.Recent findings: The last decade has seen several pivotal trials investigating IL-23 inhibitors. These agents are effective in inducing and maintaining remission of moderate-to-severe inflammatory bowel disease, including among those with prior biologic failure, and have low adverse events. IL-23 inhibitors are safe and effective for treatment of moderate-to-severe inflammatory bowel disease and appear more effective than ustekinumab for Crohn's disease. The currently available IL-23 inhibitors likely have similar efficacy, but practical considerations may influence preferences.\",\"PeriodicalId\":10776,\"journal\":{\"name\":\"Current Gastroenterology Reports\",\"volume\":\"27 1\",\"pages\":\"35\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Gastroenterology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s11894-025-00987-3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Gastroenterology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11894-025-00987-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

综述目的：本文综述了IL-23抑制剂治疗炎症性肠病的相关文献以及这些药物在临床中的作用。最近的发现：在过去的十年中，有几项研究IL-23抑制剂的关键试验。这些药物在诱导和维持中度至重度炎症性肠病的缓解方面是有效的，包括那些先前有生物学功能衰竭的患者，并且不良事件发生率低。IL-23抑制剂对于治疗中度至重度炎症性肠病安全有效，并且似乎比ustekinumab对克罗恩病更有效。目前可用的IL-23抑制剂可能具有类似的功效，但实际考虑可能会影响偏好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Interleukin-23 Inhibitors for Inflammatory Bowel Disease: Pivotal Trials and Practical Considerations.

Purpose of review: This review summarizes the literature on IL-23 inhibitors for inflammatory bowel disease and the role of these agents in clinical practice.

Recent findings: The last decade has seen several pivotal trials investigating IL-23 inhibitors. These agents are effective in inducing and maintaining remission of moderate-to-severe inflammatory bowel disease, including among those with prior biologic failure, and have low adverse events. IL-23 inhibitors are safe and effective for treatment of moderate-to-severe inflammatory bowel disease and appear more effective than ustekinumab for Crohn's disease. The currently available IL-23 inhibitors likely have similar efficacy, but practical considerations may influence preferences.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current Gastroenterology Reports Medicine-Gastroenterology

CiteScore

7.80

自引率

0.00%

发文量

期刊介绍： As the field of gastroenterology and hepatology rapidly evolves, the wealth of published literature can be overwhelming. The aim of the journal is to help readers stay abreast of such advances by offering authoritative, systematic reviews by leading experts. We accomplish this aim by appointing Section Editors who invite international experts to contribute review articles that highlight recent developments and important papers published in the past year. Major topics in gastroenterology are covered, including pediatric gastroenterology, neuromuscular disorders, infections, nutrition, and inflammatory bowel disease. These reviews provide clear, insightful summaries of expert perspectives relevant to clinical practice. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. We also provide commentaries from well-known figures in the field.